Table 2 Prevalence of peripartum depressive and anxiety symptoms across the antepartum and postpartum periods. GA = gestational age
From: Patterns of peripartum depression and anxiety during the pre-vaccine COVID-19 pandemic
|  | 24 week GA | 34 week GA | 6–8 weeks postpartum | 6 months postpartum | P- value |
|---|---|---|---|---|---|
EPDS score: mean, SD (n) | Â | Â | Â | Â | Â |
All participants | 7.06 ± 4.73 (174) | 7.24 ± 4.89 (301) | 5.79 ± 5.01 (310) | 7.45 ± 5.11 (243) | < 0.0001 |
COVID + subgroup | 6.82 ± 4.92 (130) | 6.95 ± 4.84 (235) | 5.55 ± 4.96 (241) | 7.29 ± 5.16 (189) | < 0.0001 |
EPDS score: median (range) | Â | Â | Â | Â | Â |
All participants | 7 (0.0–20) | 7 (0.0–21) | 5 (0.0–25) | 6 (0.0–25) | -- |
COVID + subgroup | 6.5 (0.0–20) | 6 (0.0–20) | 5 (0.0–25) | 7 (0.0–20) | -- |
Symptomatic Depression: n (%) | Â | Â | Â | Â | Â |
All participants | 21 (12.1%) | 44 (14.6%) | 32 (10.3%) | 50 (20.6%) | 0.0026 |
COVID + subgroup | 13 (10.0%) | 32 (13.6%) | 20 (8.3%) | 37 (19.6%) | 0.0009 |
GAD-7 score: mean, SD (n) | Â | Â | Â | Â | Â |
All participants | 4.63 ± 4.03 (174) | 5.07 ± 4.49 (298) | 3.93 ± 4.44 (309) | 5.16 ± 5 (243) | < 0.0001 |
COVID + subgroup | 4.59 ± 4.2 (130) | 4.97 ± 4.63 (233) | 3.66 ± 4.33 (240) | 5.06 ± 5.07 (189) | < 0.0001 |
GAD-7 score: median (range) | Â | Â | Â | Â | Â |
All participants | 4 (0.0–19) | 4 (0.0–21) | 3 (0.0–21) | 4 (0.0–21) | -- |
COVID + subgroup | 4 (0.0–19) | 4 (0.0–21) | 2 (0.0–21) | 4 (0.0–21) | -- |
GAD score >/= 10: n (%) | Â | Â | Â | Â | Â |
All participants | 22 (12.6%) | 45 (15.1%) | 31 (10.0%) | 42 (17.3%) | 0.014 |
COVID + subgroup | 17 (13.1%) | 36 (15.5%) | 22 (9.2%) | 33 (17.5%) | 0.0056 |
Comorbid depression/anxiety: n (%) | Â | Â | Â | Â | Â |
All participants | 28 (16.1%) | 62 (20.6%) | 42 (13.5%) | 64 (26.3%) | < 0.0001 |
COVID + subgroup | 19 (14.6%) | 45 (19.1%) | 29 (12.0%) | 49 (25.9%) | < 0.0001 |